Physician profile
Ryan A Keating
NPI 1245675982
$3,344.78
in general payments reported to CMS, 2019-2025
30 companies · $621 in 2025
The $621 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,024 · 2020: $184 · 2021: $157 · 2022: $197 · 2023: $697 · 2024: $465 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,782.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $889.98 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Novartis Pharmaceuticals Corporation | $445.36 | 2019-2025 | |
| Neuropace, INC. | $304.62 | 2019-2023 | |
| Sk Life Science, INC. | $264.39 | 2021-2025 | |
| Greenwich Biosciences, INC. | $240.19 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $132.60 | 2020 | |
| Eisai INC. | $105.70 | 2019-2025 | |
| Neurelis, INC. | $96.75 | 2022-2024 | Valtoco |
| Jazz Pharmaceuticals INC. | $96.29 | 2023 | |
| Biogen, INC. | $76.19 | 2025 | Tysabri, Skyclarys, Vumerity |
| Alexion Pharmaceuticals, INC. | $71.30 | 2024-2025 | Ultomiris |
| Abbvie INC. | $66.47 | 2023-2025 | |
| Emd Serono, INC. | $63.16 | 2019 | |
| Argenx US, INC. | $52.79 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Catalyst Pharmaceuticals, INC. | $47.87 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $39.78 | 2024-2025 | Ocrevus Zunovo |
| Aucta Pharmaceuticals, INC. | $38.05 | 2024-2025 | Motpoly Xr |
| Otter Pharmaceuticals, LLC | $32.47 | 2025 | Sympazan |
| Sumitomo Pharma America, INC. | $32.33 | 2023 | Aptiom |
| Takeda Pharmaceuticals U.S.A., INC. | $31.59 | 2025 | Hyqvia |
| Celgene Corporation | $29.51 | 2024 | Zeposia |
| Lundbeck LLC | $29.12 | 2025 | Vyepti |
| Alnylam Pharmaceuticals INC. | $27.68 | 2025 | Onpattro |
| Amneal Pharmaceuticals LLC | $25.05 | 2023 | Rytary |
| Medtronic USA, INC. | $22.84 | 2019 | |
| Boston Scientific Corporation | $18.94 | 2024 | |
| Hospira, INC. | $18.59 | 2024 | |
| Cala Health, INC. | $16.50 | 2022 | |
| Neurocrine Biosciences, INC. | $14.86 | 2024 | Ingrezza |
| Lilly USA, LLC | $13.81 | 2025 | Kisunla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Keating listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.